Liver primary target in rat and monkey (single-cell necrosis, enzyme increases); no adverse findings at 3.5x (rat) and 26.3x (monkey) exposure
“No adverse findings were associated with chronic, weekly administration of givosiran to rats and monkeys at doses that achieved exposure multiples of 3.5- and 26.3 fold, respectively when compared to exposures achieved in patients receiving the maximum recommended human dose.”